233 related articles for article (PubMed ID: 29332128)
1. Pharmacologic Characterization of Omidenepag Isopropyl, a Novel Selective EP2 Receptor Agonist, as an Ocular Hypotensive Agent.
Kirihara T; Taniguchi T; Yamamura K; Iwamura R; Yoneda K; Odani-Kawabata N; Shimazaki A; Matsugi T; Shams N; Zhang JZ
Invest Ophthalmol Vis Sci; 2018 Jan; 59(1):145-153. PubMed ID: 29332128
[TBL] [Abstract][Full Text] [Related]
2. Human experience and efficacy of omidenepag isopropyl (Eybelis®; Omlonti®): Discovery to approval of the novel non-prostaglandin EP2-receptor-selective agonist ocular hypotensive drug.
Sharif NA
Curr Opin Pharmacol; 2024 Feb; 74():102426. PubMed ID: 38168596
[TBL] [Abstract][Full Text] [Related]
3. Additive Intraocular Pressure-Lowering Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, Combined with Existing Antiglaucoma Agents in Conscious Ocular Normotensive Monkeys.
Fuwa M; Shimazaki A; Odani-Kawabata N; Kirihara T; Taniguchi T; Iwamura R; Yoneda K; Kato M; Morishima K; Shams NK
J Ocul Pharmacol Ther; 2021 May; 37(4):223-229. PubMed ID: 33600237
[No Abstract] [Full Text] [Related]
4. Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, on Aqueous Humor Dynamics in Laser-Induced Ocular Hypertensive Monkeys.
Fuwa M; Toris CB; Fan S; Taniguchi T; Ichikawa M; Odani-Kawabata N; Iwamura R; Yoneda K; Matsugi T; Shams NK; Zhang JZ
J Ocul Pharmacol Ther; 2018 Sep; 34(7):531-537. PubMed ID: 29989843
[TBL] [Abstract][Full Text] [Related]
5. Effect of PF-04217329 a prodrug of a selective prostaglandin EP(2) agonist on intraocular pressure in preclinical models of glaucoma.
Prasanna G; Carreiro S; Anderson S; Gukasyan H; Sartnurak S; Younis H; Gale D; Xiang C; Wells P; Dinh D; Almaden C; Fortner J; Toris C; Niesman M; Lafontaine J; Krauss A
Exp Eye Res; 2011 Sep; 93(3):256-64. PubMed ID: 21376717
[TBL] [Abstract][Full Text] [Related]
6. Identification of a Selective, Non-Prostanoid EP2 Receptor Agonist for the Treatment of Glaucoma: Omidenepag and its Prodrug Omidenepag Isopropyl.
Iwamura R; Tanaka M; Okanari E; Kirihara T; Odani-Kawabata N; Shams N; Yoneda K
J Med Chem; 2018 Aug; 61(15):6869-6891. PubMed ID: 29995405
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Patient Tolerability of Omidenepag Isopropyl in the Treatment of Glaucoma and Ocular Hypertension.
Matsuo M; Matsuoka Y; Tanito M
Clin Ophthalmol; 2022; 16():1261-1279. PubMed ID: 35510270
[TBL] [Abstract][Full Text] [Related]
8. Intraocular pressure-lowering effect of omidenepag isopropyl in latanoprost non-/low-responder patients with primary open-angle glaucoma or ocular hypertension: the FUJI study.
Aihara M; Ropo A; Lu F; Kawata H; Iwata A; Odani-Kawabata N; Shams N
Jpn J Ophthalmol; 2020 Jul; 64(4):398-406. PubMed ID: 32572719
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics, Safety, and Intraocular Pressure-Lowering Profile of Omidenepag Isopropyl, a Selective, Nonprostaglandin, Prostanoid EP2 Receptor Agonist, in Healthy Japanese and Caucasian Volunteers (Phase I Study).
Aihara M; Lu F; Kawata H; Tanaka Y; Yamamura K; Odani-Kawabata N; Shams NK
J Ocul Pharmacol Ther; 2019 Dec; 35(10):542-550. PubMed ID: 31674861
[No Abstract] [Full Text] [Related]
10. FP and EP2 prostanoid receptor agonist drugs and aqueous humor outflow devices for treating ocular hypertension and glaucoma.
Sharif NA; Odani-Kawabata N; Lu F; Pinchuk L
Exp Eye Res; 2023 Apr; 229():109415. PubMed ID: 36803996
[TBL] [Abstract][Full Text] [Related]
11. The prostanoid EP2 receptor agonist butaprost increases uveoscleral outflow in the cynomolgus monkey.
Nilsson SF; Drecoll E; Lütjen-Drecoll E; Toris CB; Krauss AH; Kharlamb A; Nieves A; Guerra T; Woodward DF
Invest Ophthalmol Vis Sci; 2006 Sep; 47(9):4042-9. PubMed ID: 16936121
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and intraocular pressure-lowering activity of TAK-639, a novel C-type natriuretic peptide analog, in rabbit, dog, and monkey.
Savinainen A; Prusakiewicz JJ; Oswald J; Spencer E; Lou Z; Cohen ML; Rashidzadeh H; Josiah S
Exp Eye Res; 2019 Dec; 189():107836. PubMed ID: 31626797
[TBL] [Abstract][Full Text] [Related]
13. Newly or switching effect of a selective EP2 agonist on intraocular pressure in Japanese patients with open-angle glaucoma.
Ueda K; Sakata R; Fujishiro T; Honjo M; Shirato S; Aihara M
Jpn J Ophthalmol; 2022 Sep; 66(5):434-439. PubMed ID: 35906503
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, as an ocular hypotensive drug.
Takagi Y; Nakajima T; Shimazaki A; Kageyama M; Matsugi T; Matsumura Y; Gabelt BT; Kaufman PL; Hara H
Exp Eye Res; 2004 Apr; 78(4):767-76. PubMed ID: 15037111
[TBL] [Abstract][Full Text] [Related]
15. Serotonin-2 receptor agonists as novel ocular hypotensive agents and their cellular and molecular mechanisms of action.
Sharif NA
Curr Drug Targets; 2010 Aug; 11(8):978-93. PubMed ID: 20426763
[TBL] [Abstract][Full Text] [Related]
16. Downregulation of COL12A1 and COL13A1 by a selective EP2 receptor agonist, omidenepag, in human trabecular meshwork cells.
Kumon M; Fuwa M; Shimazaki A; Odani-Kawabata N; Iwamura R; Yoneda K; Kato M
PLoS One; 2023; 18(1):e0280331. PubMed ID: 36630412
[TBL] [Abstract][Full Text] [Related]
17. Ocular hypotensive activity of BOL-303259-X, a nitric oxide donating prostaglandin F2α agonist, in preclinical models.
Krauss AH; Impagnatiello F; Toris CB; Gale DC; Prasanna G; Borghi V; Chiroli V; Chong WK; Carreiro ST; Ongini E
Exp Eye Res; 2011 Sep; 93(3):250-5. PubMed ID: 21396362
[TBL] [Abstract][Full Text] [Related]
18. Phase 2, Randomized, Dose-finding Studies of Omidenepag Isopropyl, a Selective EP2 Agonist, in Patients With Primary Open-angle Glaucoma or Ocular Hypertension.
Aihara M; Lu F; Kawata H; Iwata A; Liu K; Odani-Kawabata N; Shams NK
J Glaucoma; 2019 May; 28(5):375-385. PubMed ID: 30839416
[TBL] [Abstract][Full Text] [Related]
19. Cabergoline: Pharmacology, ocular hypotensive studies in multiple species, and aqueous humor dynamic modulation in the Cynomolgus monkey eyes.
Sharif NA; McLaughlin MA; Kelly CR; Katoli P; Drace C; Husain S; Crosson C; Toris C; Zhan GL; Camras C
Exp Eye Res; 2009 Mar; 88(3):386-97. PubMed ID: 18992242
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Omidenepag Isopropyl 0.002% Ophthalmic Solution: A Retrospective Analysis of Real-World Data in Japan.
Miki A; Miyamoto E; Ishida N; Shii D; Hori K;
Adv Ther; 2022 May; 39(5):2085-2095. PubMed ID: 35287233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
